Top

Journal of Nephrology

Published in:

01-10-2021 | Acute Kidney Injury | Original Article

Paracetamol use and lowered risk of acute kidney injury in patients with rhabdomyolysis

Authors: Maxime Desgrouas, Thierry Boulain

Published in: Journal of Nephrology | Issue 5/2021

Abstract

Background

Mortality with rhabdomyolysis-associated acute kidney injury can be as high as 80%. Experimental data from mouse models of rhabdomyolysis showed that paracetamol reduces the expected increase in serum creatinine level. We aimed to assess the association between paracetamol use and the need for starting renal replacement therapy (RRT).

Methods

We conducted a propensity score-matched cohort study in Orléans Hospital, France (a 1136-bed, public, university-affiliated and teaching hospital). All patients with serum creatine phosphokinase (CK) level > 5000 IU/L between January 1st, 2008 and December 31st, 2017 were included. A propensity score was calculated for each included patient by using multivariable logistic regression and all available baseline characteristics. The main outcome was the incidence of RRT initiation from day 1 to day 28 in the propensity score-matched cohort between patients exposed and unexposed to paracetamol.

Results

Over the study period, 1065 patients with at least one CK level measurement > 5000 IU/L were included; 40 (3.8%) had at least one RRT session. Among the 343 matched pairs, 10 (2.9%) exposed and 24 (7.0%) unexposed patients underwent RRT before day 28 (P = 0.021). Primary time-to-event analysis showed that exposure to paracetamol was significantly associated with reduced absolute risk of RRT: absolute risk difference = − 3.18% (95% CI − 5.23 to − 1.20, P = 0.001). All secondary analyses showed a significantly reduced absolute risk of RRT in patients exposed to paracetamol.

Conclusion

Our study showed a significant association between paracetamol exposure and reduced incidence of RRT among patients with rhabdomyolysis.

Graphic abstract

Available only for authorised users

Huerta-Alardín AL, Varon J, Marik PE (2004) Bench-to-bedside review: Rhabdomyolysis–an overview for clinicians. Crit Care 9:158–169. https://doi.org/10.1186/cc2978CrossRefPubMedPubMedCentral

Zutt R, van der Kooi AJ, Linthorst GE et al (2014) Rhabdomyolysis: review of the literature. Neuromuscul Disord 24:651–659. https://doi.org/10.1016/j.nmd.2014.05.005CrossRefPubMed

Brown CVR, Rhee P, Chan L et al (2004) Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 56:1191–1196. https://doi.org/10.1097/01.TA.0000130761.78627.10CrossRefPubMed

El-Abdellati E, Eyselbergs M, Sirimsi H et al (2013) An observational study on rhabdomyolysis in the intensive care unit. Exploring its risk factors and main complication: acute kidney injury. Ann Intensive Care 3:8. https://doi.org/10.1186/2110-5820-3-8CrossRefPubMedPubMedCentral

Safari S, Yousefifard M, Hashemi B et al (2016) The value of serum creatine kinase in predicting the risk of rhabdomyolysis-induced acute kidney injury: a systematic review and meta-analysis. Clin Exp Nephrol 20:153–161. https://doi.org/10.1007/s10157-015-1204-1CrossRefPubMed

McMahon GM, Zeng X, Waikar SS (2013) A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med 173:1821. https://doi.org/10.1001/jamainternmed.2013.9774CrossRefPubMedPubMedCentral

Bagley WH, Yang H, Shah KH (2007) Rhabdomyolysis. Intern Emerg Med 2:210–218. https://doi.org/10.1007/s11739-007-0060-8CrossRefPubMed

Bosch X, Poch E, Grau JM (2009) Rhabdomyolysis and acute kidney injury. N Engl J Med 361:62–72. https://doi.org/10.1056/NEJMra0801327CrossRefPubMed

Boutaud O, Moore KP, Reeder BJ et al (2010) Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci 107:2699–2704. https://doi.org/10.1073/pnas.0910174107CrossRefPubMedPubMedCentral

10.

Billings FT IV, Petracek MR, Roberts LJ II, Pretorius M (2015) Perioperative intravenous acetaminophen attenuates lipid peroxidation in adults undergoing cardiopulmonary bypass: a randomized clinical trial. PLoS ONE 10:e0117625. https://doi.org/10.1371/journal.pone.0117625CrossRefPubMed

11.

Janz DR, Bastarache JA, Peterson JF et al (2013) Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med 41:784–790. https://doi.org/10.1097/CCM.0b013e3182741a54CrossRefPubMedPubMedCentral

12.

Janz DR, Bastarache JA, Rice TW et al (2015) Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the acetaminophen for the reduction of oxidative injury in severe sepsis trial. Crit Care Med 43:534–541. https://doi.org/10.1097/CCM.0000000000000718CrossRefPubMedPubMedCentral

13.

Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179-184. https://doi.org/10.1159/000339789CrossRefPubMed

14.

Lederer DJ, Bell SC, Branson RD et al (2019) Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care Journals. Ann Am Thorac Soc 16:22–28. https://doi.org/10.1513/AnnalsATS.201808-564PSCrossRefPubMed

15.

Riley RD, Snell KI, Ensor J et al (2019) Minimum sample size for developing a multivariable prediction model: part II binary and time-to-event outcomes. Stat Med 38:1276–1296. https://doi.org/10.1002/sim.7992CrossRefPubMed

16.

Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8):757–763. https://doi.org/10.7326/0003-4819-127-8_part_2-199710151-00064CrossRefPubMed

17.

White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30:377–399. https://doi.org/10.1002/sim.4067CrossRefPubMed

18.

Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150–161. https://doi.org/10.1002/pst.433CrossRefPubMed

19.

Scheike TH, Zhang M-J (2008) Flexible competing risks regression modeling and goodness-of-fit. Lifetime Data Anal 14:464–483. https://doi.org/10.1007/s10985-008-9094-0CrossRefPubMedPubMedCentral

20.

Scheike TH, Zhang M-J, Gerds TA (2008) Predicting cumulative incidence probability by direct binomial regression. Biometrika 95:205–220. https://doi.org/10.1093/biomet/asm096CrossRef

21.

Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526. https://doi.org/10.1093/biomet/81.3.515CrossRef

22.

Munoz-Price LS, Frencken JF, Tarima S, Bonten M (2016) Handling time-dependent variables: antibiotics and antibiotic resistance. Clin Infect Dis 62:1558–1563. https://doi.org/10.1093/cid/ciw191CrossRefPubMed

23.

Hong G (2012) Marginal mean weighting through stratification: a generalized method for evaluating multivalued and multiple treatments with nonexperimental data. Psychol Methods 17:44–60. https://doi.org/10.1037/a0024918CrossRefPubMed

24.

Nguyen T-L, Collins GS, Spence J et al (2017) Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol 17:78. https://doi.org/10.1186/s12874-017-0338-0CrossRefPubMedPubMedCentral

25.

Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107. https://doi.org/10.1002/sim.3697CrossRefPubMedPubMedCentral

26.

Cervellin G, Comelli I, Benatti M et al (2017) Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management. Clin Biochem 50:656–662. https://doi.org/10.1016/j.clinbiochem.2017.02.016CrossRefPubMed

27.

Simpson SA, Zaccagni H, Bichell DP et al (2014) Acetaminophen attenuates lipid peroxidation in children undergoing cardiopulmonary bypass. Pediatric Criti Care Med 15:503–510. https://doi.org/10.1097/PCC.0000000000000149CrossRef

28.

On behalf of the French Intensive Care Renal Network (F.I.R.N), Candela N, Silva S et al (2020) Short- and long-term renal outcomes following severe rhabdomyolysis: a French multicenter retrospective study of 387 patients. Ann Intensive Care 10:27. https://doi.org/10.1186/s13613-020-0645-1CrossRef

29.

Patanwala AE, Aljuhani O, Bakhsh H, Erstad BL (2018) Effect of Acetaminophen on the Prevention of Acute Kidney Injury in Patients With Sepsis. Ann Pharmacother 52(1):48–53. https://doi.org/10.1177/1060028017728298CrossRefPubMed

30.

Reeder BJ, Svistunenko DA, Cooper CE, Wilson MT (2004) The radical and redox chemistry of myoglobin and hemoglobin: from in vitro studies to human pathology. Antioxid Redox Signal 6:954–966. https://doi.org/10.1089/ars.2004.6.954CrossRefPubMed

31.

AlBasher G, Alfarraj S, Alarifi S et al (2020) Nephroprotective role of selenium nanoparticles against glycerol-induced acute kidney injury in rats. Biol Trace Elem Res 194:444–454. https://doi.org/10.1007/s12011-019-01793-5CrossRefPubMed

32.

Reis NG, Francescato HDC, de Almeida LF et al (2019) Protective effect of calcitriol on rhabdomyolysis-induced acute kidney injury in rats. Sci Rep 9:7090. https://doi.org/10.1038/s41598-019-43564-1CrossRefPubMedPubMedCentral

33.

Guerrero-Hue M, García-Caballero C, Palomino-Antolín A et al (2019) Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. FASEB J 33:8961–8975. https://doi.org/10.1096/fj.201900077RCrossRefPubMed

34.

Panizo N, Rubio-Navarro A, Amaro-Villalobos JM et al (2015) Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press Res 40:520–532. https://doi.org/10.1159/000368528CrossRefPubMed

35.

Guerrero-Hue M, Rubio-Navarro A, Sevillano Á et al (2018) Adverse effects of the renal accumulation of haem proteins. Novel Ther Approaches Nefrol (Engl Ed) 38:13–26. https://doi.org/10.1016/j.nefroe.2018.01.003CrossRef

36.

Plewes K, Kingston HWF, Ghose A et al (2018) Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe falciparum malaria: a randomized, controlled, open-label trial. Clin Infect Dis 67:991–999. https://doi.org/10.1093/cid/ciy213CrossRefPubMedPubMedCentral

37.

Cooper DJ, Plewes K, Grigg MJ et al (2018) The effect of regularly dosed paracetamol versus no paracetamol on renal function in Plasmodium knowlesi malaria (PACKNOW): study protocol for a randomised controlled trial. Trials 19:250. https://doi.org/10.1186/s13063-018-2600-0CrossRefPubMedPubMedCentral

38.

Prescott LF (1980) Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol. https://doi.org/10.1111/j.1365-2125.1980.tb01812.xCrossRefPubMedPubMedCentral

39.

Chen C-Y, Lin Y-R, Zhao L-L et al (2013) Clinical factors in predicting acute renal failure caused by rhabdomyolysis in the ED. Am J Emerg Med 31:1062–1066. https://doi.org/10.1016/j.ajem.2013.03.047CrossRefPubMed

40.

Heyne N, Guthoff M, Krieger J, Haap M, Häring H-U (2012) High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series. Nephron Clin Pract 121:c159–c164. https://doi.org/10.1159/000343564CrossRefPubMed

41.

Petejova N, Martinek A (2014) Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 18:224. https://doi.org/10.1186/cc13897CrossRefPubMedPubMedCentral

42.

Zeng X, Zhang L, Wu T, Fu P (2014) Continuous renal replacement therapy (CRRT) for rhabdomyolysis (review). Cochrane Database Syst Rev 6:CD008566. https://doi.org/10.1002/14651858.CD008566.pub2CrossRef

Title: Paracetamol use and lowered risk of acute kidney injury in patients with rhabdomyolysis
Authors: Maxime Desgrouas
Thierry Boulain
Publication date: 01-10-2021
Publisher: Springer International Publishing
Keywords: Acute Kidney Injury
Paracetamol
Acute Kidney Injury
Published in: Journal of Nephrology / Issue 5/2021
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-020-00950-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Graphic abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study

Risk of chronic kidney disease in women with a history of preterm delivery: Tehran Lipid and Glucose Study

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study

Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study

Effect of sodium bicarbonate supplementation on the renin-angiotensin system in patients with chronic kidney disease and acidosis: a randomized clinical trial

National Cardiovascular Data Registry-Acute Kidney Injury (NCDR) vs. Mehran risk models for prediction of contrast-induced nephropathy and need for dialysis after coronary angiography in a German patient cohort

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials